Medistim Stock Analysis: An 80% Gross-Margin Surgical Niche Faces Its Most Important Adoption Test

0Sign in to vote or save

Hospitals buy proof that bypass grafts work, but Medistim’s valuation depends on turning strong clinical logic into routine surgical practice.

Comments

Nothing yet. Say the first thing.